Arax Advisory Partners’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Arax Advisory Partners’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$26.2K	Sell	874 -1,461	-63%	-$48.4K	﹤0.01%	1975
2025 Q4	$76.4K	Buy	2,335 +1,778	+319%	+$57.4K	﹤0.01%	1434
2025 Q3	$19.3K	Buy	557 +124	+29%	+$3.97K	﹤0.01%	2277
2025 Q2	$12.1K	Buy	433 +393	+983%	+$10.5K	﹤0.01%	1881
2025 Q1	$1K	Hold	40	–	–	﹤0.01%	2302
2024 Q4	$1.1K	Hold	40	–	–	﹤0.01%	2154
2024 Q3	$1.15K	Buy	+40	New	+$1.09K	﹤0.01%	2209
2022 Q4	–	Sell	-21	Closed	-$1K	–	1299
2022 Q3	$1K	Buy	+21	New	+$1.08K	﹤0.01%	1075

Other funds holding LKFT

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arax Advisory Partners's LKFT Position: Q1 2026 in Review

Arax Advisory Partners reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 63% in Q1 2026, selling an estimated $48.4K and leaving 874 shares worth $26.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1975.

Arax Advisory Partners first reported a position in LKFT in Q3 2022 and has held it in 8 quarters since. The position peaked at $76.4K in Q4 2025. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

Arax Advisory Partners held 874 shares of Lakefront Biotherapeutics American Depositary Shares worth $26.2K as of Q1 2026.
Arax Advisory Partners sold 1,461 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $48.4K.
Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #1975 holding.
Arax Advisory Partners first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2022 and has held it in 8 quarters since.
Arax Advisory Partners's Lakefront Biotherapeutics American Depositary Shares position peaked at $76.4K in Q4 2025.
90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.